Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $81,175.00 in Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 3,247 shares of SiBone stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $25.00, for a total transaction of $81,175.00. Following the transaction, the insider directly owned 211,250 shares in the company, valued at $5,281,250. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The stock was sold at an average price of $22.50, for a total transaction of $84,105.00.
• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total transaction of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total transaction of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total transaction of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total transaction of $87,002.25.

SiBone Stock Performance

Shares of SIBN stock opened at $24.24 on Monday. SiBone has a 52-week low of $11.48 and a 52-week high of $25.92. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.15 and a current ratio of 7.58. The company has a 50-day simple moving average of $19.81 and a two-hundred day simple moving average of $16.59. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -78.19 and a beta of 0.64.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. The firm had revenue of $55.70 million during the quarter, compared to analyst estimates of $55.31 million. Research analysts anticipate that SiBone will post -0.34 EPS for the current fiscal year.

Institutional Investors Weigh In On SiBone

Large investors have recently modified their holdings of the stock. Versant Capital Management Inc lifted its position in shares of SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares during the last quarter. State of Wyoming grew its stake in shares of SiBone by 70.8% during the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after acquiring an additional 4,490 shares during the period. Inceptionr LLC bought a new position in shares of SiBone during the 1st quarter worth $156,000. ADAR1 Capital Management LLC bought a new position in shares of SiBone during the 1st quarter worth $159,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in SiBone in the 1st quarter worth about $204,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SIBN shares. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of SiBone in a research report on Tuesday, November 3rd. Truist Financial lifted their target price on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Finally, UBS Group boosted their price target on shares of SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Key SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
• Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
• Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
• Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.